Kinarus Therapeutics Holding AG
SIX:KNRS

Watchlist Manager
Kinarus Therapeutics Holding AG Logo
Kinarus Therapeutics Holding AG
SIX:KNRS
Watchlist
Price: 15 CHF 416 566.67% Market Closed
Market Cap: 19.5B CHF
Have any thoughts about
Kinarus Therapeutics Holding AG?
Write Note

Net Margin
Kinarus Therapeutics Holding AG

0%
Current
0.1%
Average
2.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.9m
/
Revenue
0

Net Margin Across Competitors

Country CH
Market Cap 19.5B CHF
Net Margin N/A
Country US
Market Cap 40.9B USD
Net Margin
8%
Country US
Market Cap 31.3B USD
Net Margin
5%
Country IE
Market Cap 15.4B EUR
Net Margin
14%
Country US
Market Cap 19.2B USD
Net Margin
0%
Country IN
Market Cap 1.6T INR
Net Margin
9%
Country CN
Market Cap 116.3B CNY
Net Margin
0%
Country UK
Market Cap 12.1B GBP
Net Margin
7%
Country SG
Market Cap 18.9B SGD
Net Margin
14%
Country CN
Market Cap 88.7B CNY
Net Margin
-2%
Country TR
Market Cap 384.4B TRY
Net Margin
29%
No Stocks Found

Kinarus Therapeutics Holding AG
Glance View

Market Cap
19.5B CHF
Industry
Airlines

Kinarus Therapeutics Holding AG is a Swiss biopharmaceutical company at the forefront of innovative drug development, particularly in the realm of advanced therapies for respiratory and viral diseases. Founded with the mission to address significant unmet medical needs, Kinarus is pioneering the use of its proprietary therapeutic platform that targets mechanisms associated with chronic and infectious conditions. The company is making strides with its lead candidate, KIN001, a novel treatment designed to combat COVID-19 while also addressing the long-term implications of the disease, illustrating Kinarus’s commitment to not only responding to immediate health crises but also improving patient outcomes over the long term. Investors will find Kinarus's strategic focus compelling, as it centers on leveraging its unique drug candidates to tap into lucrative markets with expansive potential for growth. The company collaborates with academic institutions and industry partners, reinforcing its innovative edge and enhancing its research capabilities. Positioned in the robust European biotechnology landscape and with a skilled leadership team that emphasizes sustainable development, Kinarus stands out as an attractive investment opportunity for those looking to engage in the life sciences sector. Through its advancements, Kinarus aims to deliver both breakthrough therapies and significant shareholder value, making it a noteworthy player in the ever-evolving healthcare market.

KNRS Intrinsic Value
Not Available

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-13.9m
/
Revenue
0
What is the Net Margin of Kinarus Therapeutics Holding AG?

Based on Kinarus Therapeutics Holding AG's most recent financial statements, the company has Net Margin of 0%.